Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
RESEARCH TOOLSreports
Holding APGE?
Track your performance easily
APGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.85 - $72.29
Previous Close$47.71
Volume606.24K
Average Volume (3M)460.53K
Market Cap
$2.75B
Enterprise Value$2.24B
Total Cash (Recent Filing)$526.05M
Total Debt (Recent Filing)$12.14M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Mar 11, 2025EPS Estimate
-$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding58,513,198
10 Day Avg. Volume590,567
30 Day Avg. Volume460,530
Standard Deviation0.29
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.80
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.54
Forecast
1Y Price Target
$93.80Price Target Upside96.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Apogee Therapeutics, Inc. News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $25.85 and its highest was $72.29 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2025 which is in 79 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.863 earnings per share for the quarter, beating the consensus estimate of -$0.879 by $0.016.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -$1.08.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 45,026,554 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$0.863 in its last earnings report, beating expectations of -$0.879. Following the earnings report the stock price went down -5.144%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Among the largest hedge funds holding Apogee Therapeutics, Inc.’s share is Driehaus Capital Management LLC. It holds Apogee Therapeutics, Inc.’s shares valued at 149M.
---
Apogee Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.80 (96.60% Upside)
$93.80 (96.60% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 190.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $990.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.6%
Last 30 Days ▲ 42.6%
Last 30 Days ▲ 42.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
92.45%
12-Months-Change
Fundamentals
Return on Equity
-25.65%
Trailing 12-Months
Asset Growth
82.05%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$93.80
▲(96.60% Upside)
Technical Analysis
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+36.38%
reiterated a buy rating 10 months ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +36.38% per trade.
---